Is Amgen’s Acquisition of Five Prime a Good Move for the Big Biotech?

1 min read

Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss why Amgen needs to seek out this potential growth and whether Five Prime’s pipeline is worth the premium Amgen paid for it.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Fortinet Partners With Linksys to Secure Work-From-Home Employees

Next Story

3 Reasons Adobe Stock Is a Reopening Play

Latest from Blog